GSKNCT04950127PBCLinerixibatNumeric Rating Scale
…n placebo, they rarely led to treatment discontinuation.Funding GSK [212620/ NCT04950127]. Previously presented at EASL 2025 (prese…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04950127 ×
NCT04950127
This funder is selected. Its supporting articles are shown below.